Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30067548 | 1.00 | KDM1A (1.00) | KDM1A | |
| SCHEMBL23496010 | 1.00 | KDM1A (1.00) | KDM1A | |
| Oxalic Acid SCHEMBL30067656 | 0.98 | KDM1A (0.95) | KDM1A | |
| SCHEMBL30067552 | 0.96 | KDM1A (0.93) | KDM1A | |
| Maleic Acid SCHEMBL30067608 | 0.95 | KDM1A (0.91) | KDM1A | |
| SCHEMBL30067611 | 0.95 | KDM1A (0.91) | KDM1A | |
| Fumaric Acid SCHEMBL31000952 | 0.95 | KDM1A (0.91) | KDM1A | |
| SCHEMBL27171696 | 0.94 | KDM1A (0.88) | KDM1A | |
| SCHEMBL31000932 | 0.94 | KDM1A (0.88) | KDM1A | |
| SCHEMBL20512631 | 0.94 | KDM1A (1.00) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295660-A1 | METHODS OF TREATING NF1-MUTANT TUMORS USING LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2025-09-25 | — | — | US | claimed |
| US-12419858-B2 | Salt of terphenyl compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-09-23 | — | — | US | claimed |
| US-20250275969-A1 | METHODS OF TREATING MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) USING LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2025-09-04 | — | — | US | claimed |
| EP-4058151-B1 | NOVEL SALT OF TERPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-05-21 | — | — | EP | claimed |
| US-20250049757-A1 | COMBINATORY THERAPY FOR CANCER USING BIPHENYL COMPOUND AND IMMUNE CHECKPOINT MOLECULE REGULATOR | ASTEX PHARMACEUTICALS, INC. | 2025-02-13 | — | — | US | claimed |
| EP-4408417-A1 | COMBINATORY THERAPY FOR CANCER USING BIPHENYL COMPOUND AND IMMUNE CHECKPOINT MOLECULE REGULATOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2024-08-07 | — | — | EP | claimed |
| US-20240228438-A1 | SOLID FORMS OF SALTS OF 4-[5-[(3S)-3-AMINOPYRROLIDINE-1-CARBONYL]-2-[2-FLUORO-4-(2- HYDROXY-2-ETHYLPROPYL)PHENYL]PHENYL]-2-FLUORO-BENZONITRILE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-11 | — | — | US | claimed |
| EP-4337638-A1 | SOLID FORMS OF SALTS OF 4-[5-[(3S)-3-AMINOPYRROLIDINE-1-CARBONYL]-2-[2-FLUORO-4-(2-HYDROXY-2-ETHYLPROPYL)PHENYL]PHENYL]-2-FLUORO-BENZONITRILE | Astex Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2023217784-A1 | METHODS OF TREATING NF1-MUTANT TUMORS USING LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2023-11-16 | — | — | WO | claimed |
| WO-2023217758-A1 | METHODS OF TREATING MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) USING LSD1 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2023-11-16 | — | — | WO | claimed |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-29 | — | — | US | claimed |
| EP-4058151-A1 | NOVEL SALT OF TERPHENYL COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-09-21 | — | — | EP | claimed |
| EP-4058018-A1 | METHODS OF TREATING LSD1-RELATED DISEASES AND DISORDERS WITH LSD1 INHIBITORS | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-09-21 | — | — | EP | claimed |
| WO-2021095835-A1 | NOVEL SALT OF TERPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-20 | — | — | WO | claimed |
| WO-2021095840-A1 | METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-20 | — | — | WO | claimed |
| US-10723742-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-28 | — | — | US | claimed |
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | claimed |
| EP-3632443-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-04-08 | — | — | EP | claimed |
| EP-3633380-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-04-08 | — | — | EP | claimed |
| EP-3381896-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275969-A1 | METHODS OF TREATING MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) USING LSD1 INHIBITORS | KDM1B, KDM3B, KDM1A | KDM1A 3/4885 |
| US-20250049757-A1 | COMBINATORY THERAPY FOR CANCER USING BIPHENYL COMPOUND AND IMMUNE CHECKPOINT MOLECULE REGULATOR | PDCD1LG2, CD274, PDCD1 | KDM1A 895/4885 |
| US-10723742-B2 | Biphenyl compound or salt thereof | KDM1B, BMI1, HDAC1 | KDM1A 5/4885 |
| US-12419858-B2 | Salt of terphenyl compound | BET1, PAH, SORBS1 | KDM1A 1530/4885 |
| US-20250295660-A1 | METHODS OF TREATING NF1-MUTANT TUMORS USING LSD1 INHIBITORS | KDM1B, KDM2A, KDM1A | KDM1A 3/4885 |
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | INMT, CARM1, KDM1B | KDM1A 7/4885 |
| US-20240228438-A1 | SOLID FORMS OF SALTS OF 4-[5-[(3S)-3-AMINOPYRROLIDINE-1-CARBONYL]-2-[2-FLUORO-4-(2- HYDROXY-2-ETHYLPROPYL)PHENYL]PHENYL]-2-FLUORO-BENZONITRILE | AFF4, SKP1, CYP3A4 | KDM1A 286/4885 |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | KDM1B, KDM1A, DOT1L | KDM1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.